Drug & intervention

tenofovir disoproxil fumarate

RxCUI 322248

Clinical trials47
Recruiting2
Related conditions20
Synonyms1

Medication research snapshot

CureCurrent currently links 47 distinct registered clinical trials to tenofovir disoproxil fumarate through its RxNorm intervention mappings. 2 of those studies have the registry status “recruiting” (4%). These are registry statuses, not availability guarantees, study results or evidence of effectiveness.

The leading sponsor shown in this linked dataset is National Institute of Allergy and Infectious Diseases (NIAID), associated with 21 distinct linked trials. This is a count of records, not a ranking of the sponsor's scientific quality.

The highest-count mapped research city in the current result is New York, United States. Only site locations available in the published registry projection are counted; some trial sites may be missing or outdated.

The most common trial-reported condition associated with this drug concept is HIV Infections (34 linked trials). A registry intervention association is not proof that a drug is approved or effective for that condition.

Numbers are derived from CureCurrent's current ClinicalTrials.gov projection and conservative MONDO/RxNorm mappings. See sources, counting rules and limitations and verify eligibility or clinical findings with the original study record.

Understanding this RxNorm record

RxNorm identifiers distinguish ingredients, specific strengths, dose forms, and branded products. They help connect equivalent terminology across data sources; an RxNorm entry does not by itself establish that a product is currently marketed, approved for a particular use, or appropriate for an individual.

Clinical-trial associations reflect registry-reported intervention names and verified mappings where available. A medication listed in a trial may be investigational for that condition. Consult the original study record and official prescribing information for indications and safety details.

Terminology source: National Library of Medicine RxNorm. Trial source: ClinicalTrials.gov.

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

tenofovir disoproxil fumarate

Wikidata Q27132754 ↗
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized StudyNCT05652478 · 2026-09-24
RECRUITING
Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's DiseaseNCT06356662 · 2024-01-23
RECRUITING
Pharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in BotswanaNCT04862975 · 2024-01-09
COMPLETED
PK of TAF and TDF for PrEP in Pregnant and Postpartum WomenNCT04937881 · 2022-06-13
COMPLETED
Optimization of Antiretroviral TherapyNCT02935075 · 2018-03-05
COMPLETED
Modifiers of Tenofovir in the Female Genital TractNCT03377608 · 2017-11-17
COMPLETED
A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral DrugsNCT03537404 · 2017-04-24
COMPLETED
A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line TreatmentNCT01709084 · 2013-10-02
COMPLETED
Dose Optimisation of Stavudine for the Treatment of HIV InfectionNCT02670772 · 2012-07-01
COMPLETED
Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk WomenNCT01505114 · 2012-06-01
COMPLETED
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 YearsNCT00799864 · 2011-01-01
COMPLETED
Bone Mineral Density Substudy - An Ancillary Study to MTN-003NCT00729573 · 2009-11-01
COMPLETED
Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in WomenNCT00705679 · 2009-08-01
COMPLETED
Examining Hair to Determine Tenofovir ExposureNCT00903084 · 2009-06-01
COMPLETED
Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected AdultsNCT00608569 · 2009-03-01
COMPLETED
Efficacy and Safety of Switching From Retrovir to Tenofovir or Abacavir in HIV-infected PatientsNCT00647244 · 2008-06-01
COMPLETED
Adherence and Acceptability to and Blood Levels of Tenofovir Gel and Tablets in HIV Uninfected WomenNCT00592124 · 2008-06-01
COMPLETED
NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV TransmissionNCT00089505 · 2006-11-01
COMPLETED
Safety and Blood Levels of Tenofovir Disoproxil Fumarate in HIV Infected Pregnant Women and Their BabiesNCT00120471 · 2006-11-01
COMPLETED
Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male VolunteersNCT00648817 · 2006-07-01
COMPLETED
Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected ChildrenNCT00260078 · 2006-02-01
COMPLETED
Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug TherapyNCT00109603 · 2005-05-01
COMPLETED
Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected AdultsNCT00119379 · 2005-04-01
COMPLETED
Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative MenNCT00131677 · 2005-02-01
COMPLETED
Preventing Sexual Transmission of HIV With Anti-HIV DrugsNCT00074581 · 2005-02-01
COMPLETED
Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIVNCT00122486 · 2004-07-01
COMPLETED
Safety of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine/TDF in HIV Infected Pregnant Women and Their InfantsNCT00076791 · 2004-03-01
COMPLETED
Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive AdultsNCT00051831 · 2003-10-01
COMPLETED
Phase II Comparator Study of Substitution of Tenofovir or Abacavir Receiving Thymidine Analogue as Part of HAART.NCT00270556 · 2003-01-01
COMPLETED
Tenofovir Disoproxil Fumarate (TDF) in HIV-1 Patients Who Have Never Taken Anti-HIV DrugsNCT00016588 · 2001-05-01
COMPLETED
Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug CombinationsNCT00011089 · 2001-02-01
UNKNOWN
A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV InfectionNCT00002453 · 1999-12-01
COMPLETED
A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIVNCT00033163
COMPLETED
Study of Anti-HIV Therapy IntensificationNCT00034086
COMPLETED
Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug ResistanceNCT00046033
COMPLETED
Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIVNCT00027339
COMPLETED
Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected PeopleNCT00028366
COMPLETED
A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior TherapyNCT00102206
COMPLETED
Three Month Course of Anti-HIV Medications for People Recently Infected With HIVNCT00087464
WITHDRAWN
Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIVNCT00122512
TERMINATED

Leading sponsors

National Institute of Allergy and Infectious Diseases (NIAID)21Gilead Sciences9Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections2FHI 3602Aarhus University Hospital1Centers for Disease Control and Prevention1Duke University1Janssen Sciences Ireland UC1Janssen-Cilag International NV1Public Health Foundation Enterprises, Inc.1R-Pharm1Replicor Inc.1Shanghai Public Health Clinical Center1The Fourth Affiliated Hospital of Zhejiang University School of Medicine1University of California, Los Angeles1

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.